
Please try another search
(Reuters) - Novavax (NASDAQ:NVAX) Inc's shares plunged nearly 20% in premarket trading on Tuesday due to uncertainty over global demand for the company's COVID-19 vaccine following a slow start to deliveries.
The company said in September it had targeted for the delivery of at least 2 billion doses of its COVID-19 vaccine in 2022. Novavax said on Monday it delivered about 42 million doses globally in the first quarter.
Serum Institute of India, the world's biggest vaccine maker, also produces the company's COVID-19 vaccine under the brand name Covovax.
Novavax continues to see low vaccination rates across low-income countries, Chief Business and Commercial Officer John Trizzino said on a conference call.
"To date, we have not yet received an order from Gavi and the timing and quantities of future orders to deliver 2373 (the vaccine) to the COVAX facility are unclear," Trizzino said.
COVAX, a program aimed at equitable access to COVID-19 vaccines, is backed by the World Health Organization and global vaccine alliance Gavi.
Novavax's COVID-19 vaccine is based on a more conventional technology and was expected to persuade some skeptics of the mRNA technology used by companies such as Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).
However, Novavax has been plagued by manufacturing and regulatory delays, as well as a slow uptake in key markets such as the European Union.
The company on Monday reiterated its forecast for total revenue of $4 billion to $5 billion for 2022, saying it expects shipments to key markets and sales to increase in the second quarter.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.